Navigation Links
NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
Date:9/27/2007

ANN ARBOR, Mich., Sept. 27 /PRNewswire/ -- The National Institute of Standards and Technology (NIST) has selected Velcura Therapeutics, Inc. as an award winner in the Commerce Department's Advanced Technology Program (ATP), a peer-reviewed competition. NIST announced today that $2 million was awarded to the early-phase Michigan biotechnology company developing drug therapies to treat osteoporosis, bone cancer, bone fractures, and other bone disorders.

Velcura scientists have discovered a family of small molecules that possess characteristics of dual-action therapies, both stimulating bone formation and inhibiting loss. "These molecules are rapidly cleared from the blood stream, so these new drugs offer low systemic exposure, reduced off- target effects and extended time on target resulting in increased efficacy," according to Michael W. Long, PhD, president and CEO of Velcura Therapeutics, Inc. "This makes them effective agents for cancer patients and Velcura will start clinical trials I Multiple Myeloma patients for its first therapy, VEL- 0230, in early 2008."

Velcura's ATP funding supports the development of improved, or second- generation, molecules for use in bone diseases requiring long-term therapy, such rheumatoid arthritis or osteoporosis. "Velcura will use the ATP funding to invent new types of therapeutic molecules that retain the advantages of the current generation of compounds and their dual-action effects," Dr. Long added.

The ATP choose Velcura for its innovative approaches both at the level of medicinal chemistry and in the area of bone cell assay development. Velcura's new therapy could have a major economic impact on the treatment of many bone diseases such as osteoporosis that affects more than 10 million Americans. Current projections indicate a more than $60 billion market worldwide for diagnosis and treatment of the bone disease by 2020.

About Velcura Therapeutics(R), Inc.

Velcura Therapeutics Inc. is an ea
'/>"/>

SOURCE Velcura Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pelosi: Bush Veto of Stem Cell Bill Says No to the Hopes of Million of Families Across America
2. Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million Annually
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
5. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
6. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
7. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
8. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
9. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
10. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
11. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 CytRx Corporation ... and development company specializing in oncology, today announced ... trial evaluating aldoxorubicin compared to topotecan in subjects ... have relapsed or were refractory to prior chemotherapy. ... chemotherapeutic agent, doxorubicin. CytRx has received Orphan Drug ...
(Date:9/29/2014)... and PARIS , Sept. ... and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced ... investigational therapy that blocks IL-4 and IL-13 signaling, met ... chronic sinusitis with nasal polyps (CSwNP) who did not ... suggest the potential of dupilumab for use in the ...
(Date:9/29/2014)... et SAN DIEGO , ... Ltd. (ci-après désignée Daiichi Sankyo) (TSE : 4568) et ... la conclusion d,un accord de fusion définitif en ... totalité des actions ordinaires en circulation d,Ambit Biosciences ... le biais d,une offre publique d,achat qui sera ...
Breaking Medicine Technology:CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 2Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 3Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 4Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 5Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 6Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 7Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9
(Date:9/30/2014)... September 30, 2014 World of Children ... founder of the nonprofit, Friends Without A Border (FWAB) ... for building a hospital in Cambodia that has become ... Izu first encountered Cambodia’s appalling lack of pediatric healthcare ... disabilities and illnesses during a photography trip in 1993. ...
(Date:9/30/2014)... 30, 2014 During this online ... approaches to health including achieving hormonal balance, relieving ... and detoxification. , The details ... Date: October 6-9, 2014, Location: Online Event, Registration: ... http://www2.hotzehwc.com/naturalhealthsummitregistration , Monday, October 6th, Steven F. ...
(Date:9/30/2014)... September 30, 2014 AutoTex PINK ... the iconic pink ribbon in support of breast cancer ... month for businesses and non-profits to “go pink” -- ... , AutoTex PINK is a woman-owned company that is ... They are committed to partnering with their customers to ...
(Date:9/30/2014)... September 30, 2014 Timber Home Living Magazine ... for the Olsen family’s reclaimed Douglas fir timber frame home ... home’s journey from architectural planning, to the frame raising, to ... to New Energy Works, after following the timber framing company ... build their dream vacation home on land they fell in ...
(Date:9/30/2014)... Oxnard, CA (PRWEB) September 30, 2014 ... the Anacapa Dental Art Institute in Oxnard and Thousand ... Bangalore today and tomorrow to provide training on full ... previous dental work, placing implants, providing cosmetic dentistry, correcting ... Dr. Jivraj said. , Dr. Jivraj, who has traveled ...
Breaking Medicine News(10 mins):Health News:Nobel Prize For Child Advocates Announces 2014 Health Award Honoree 2Health News:Nobel Prize For Child Advocates Announces 2014 Health Award Honoree 3Health News:Hotze Health & Wellness Center Announces First Natural Health Summit 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 3Health News:Reclaimed Timber Frame Home By New Energy Works Featured in Timber Home Living Magazine 2Health News:Reclaimed Timber Frame Home By New Energy Works Featured in Timber Home Living Magazine 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 4Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 5
... 27 (HealthDay News) -- Arizona Congresswoman Gabrielle Giffords began ... forward for the lawmaker who was shot in the ... Memorial Hermann Hospital could last several months. As a ... insert a valve into her breathing tube, the ...
... January 27, 2011 Screening patients in the intensive ... cost savings for the whole hospital, according to a ... the February issue of the American Journal of ... the Association for Professionals in Infection Control and Epidemiology. ...
... , THURSDAY, Jan. 27 (HealthDay News) -- Only 42 ... and can therefore be categorized as "great sleepers," according to ... Poll" found that great sleepers get an average of about ... sleeper gets an average of seven hours and nine minutes ...
... News) -- Electroshock devices, currently classified by the U.S. Food ... severe depression, could be downgraded to medium risk this year. ... to discuss reclassifying the devices, which would pave the way ... illnesses. , , A medium-risk classification would put the devices ...
... continue dating a girlfriend who has cheated on them with ... according to new research from a University of Texas at ... are more likely to continue dating a man who has ... homosexual affair. The study, published last month in the ...
... in China have demonstrated interferon-alpha (IFN-a) is associated with ... erythematosus (SLE). For the first time, IFN-a priming was ... crucial step in plaque build-up. This activation of the ... atherosclerosis risk in SLE. Full findings of this novel ...
Cached Medicine News:Health News:Rep. Giffords' Intensive Rehab Under Way 2Health News:Rep. Giffords' Intensive Rehab Under Way 3Health News:Study finds MRSA screening saves hospitals money 2Health News:Loving Your Bedroom May Be Key to Good Sleep 2Health News:FDA May Ease Up on Electroshock Devices 2Health News:FDA May Ease Up on Electroshock Devices 3Health News:Men more likely to stick with girlfriends who sleep with other women than other men 2Health News:Researchers uncover link to increased atherosclerosis risk in lupus patients 2
Used with T-tubes to collect drainage after cholecystectomy. Includes T-tube adapter and two adjustable latex rubber belts....
Used following open gallbladder procedure to drain bile. Often attached to Bard bile bag....
Silicone Flat Hubless Drains...
Bard® Channel Drain...
Medicine Products: